Waystar (WAY) Q3 2026 Earnings Call Transcript

Waystar reported Q3 2026 revenue of $325.6 million, up 21% year over year (10% organic), and adjusted EBITDA of $139.3 million, up 24%, with a 42.8% margin. It set FY2026 revenue guidance at $1.277 billion–$1.287 billion, citing longer large-client implementations, the print-to-digital transition in patient payments, and slower Iodine revenue recognition; adjusted EBITDA guidance increased to $543 million–$549 million. Bookings rose 25% year to date and large-client implementation backlog increased 50%, while AltitudeAI offerings accounted for 43% of Q3 bookings.

Analysis

The key investment tension is conversion, not demand: bookings and backlog are expanding, but large deployments may take 12–18 months to monetize. That lengthens the payback window and raises the risk that investors capitalize bookings as if they were near-term revenue. Iodine adds a second conversion test: outcome-based pricing can support customer adoption, but recognized revenue depends on implementation and demonstrated performance. Bookings are not proof of realized economics.

Near term, the implied Q4 growth slowdown is a multiple risk for WAY, even with higher EBITDA expectations. Margin expansion partly reflects favorable mix, including less lower-margin revenue; it should not be read as clean evidence that the top-line engine is accelerating. The print-to-digital transition may be structurally margin-positive yet still reduce patient-payment revenue over a multiyear period. Stable retention offers a cushion, but does not by itself establish faster expansion.

Contrarian view: a sharp reaction to Q4 growth could overstate deterioration if backlog converts and FY27 growth firms. Conversely, management’s timing explanation could understate duration risk: delayed implementations and performance-based billing push revenue further out and make the backlog less informative without conversion data. AI booking share is an adoption signal, not yet evidence of incremental pricing power or productivity economics. Watch implementation starts, backlog-to-revenue conversion, Iodine realized revenue, and NRR. This is a conditional setup, not a clear earnings-driven buy.

Key Decisions for Investors

• Avoid chasing WAY immediately after the results. Consider a staged long only if the stock stabilizes and next-quarter FY27 guidance supports low-double-digit organic growth with credible implementation conversion; size for continued near-term multiple volatility.
• Treat the 50% large-deal backlog increase as a watch item, not an earnings substitute. Upgrade the thesis if management reports faster implementation starts and measurable backlog conversion; cut exposure if backlog keeps growing while organic revenue or NRR weakens.
• Keep Iodine as a separate execution monitor: verify that performance-based contracts produce recognized revenue and that early-adopter outcomes persist across a broader client cohort. Weak conversion would falsify the claim that current bookings underpin FY27 accretion.
• Risk markers: further patient-payment revenue deterioration beyond the stated transition, weaker-than-historical retention, or FY27 guidance below the company’s low-double-digit growth objective would argue for underweighting WAY; improving conversion and revenue guidance without margin deterioration would support adding.